Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Disc Medicine, Inc. IRON NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$110.25
+56.4%

Disc Medicine, Inc. (IRON) is a Biotechnology company in the Healthcare sector, currently trading at $70.48. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is IRON = $110 (+56.4% upside).

Valuation: IRON trades at a trailing Price-to-Earnings (P/E) of -11 (S&P 500 average ~25).

Net income is $212M (loss), growing at -67.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $740M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 21.94 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $807M.

Analyst outlook: 11 / 11 analysts rate IRON as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 93/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$110.25
▲ 56.43% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Disc Medicine, Inc., the average price target is $110.25, with a high forecast of $153.00, and a low forecast of $75.00.
Highest Price Target
$153.00
Average Price Target
$110.25
Lowest Price Target
$75.00

IRON SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 93/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IRON

✓
VALUE Pass
93/100
IRON trades at a trailing Price-to-Earnings (P/E) of -11 (S&P 500 average ~25). Forward PEG -5.35 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.89. Analyst consensus target is $110, implying +56.1% from the current price $70. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
IRON: +0%/yr revenue is, -67.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet IRON: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 21.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
IRON: Gross margin is 0% (+0 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 11 / 11 analysts rate IRON as buy (100%). Analyst consensus target is $110 (+56.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range30.82-99.5
Volume346.84K
Avg Volume (30D)702.02K
Market Cap$2.69B
Beta (1Y)2.54
Share Statistics
EPS (TTM)-6.01
Shares Outstanding$35.3M
IPO Date2020-08-12
Employees94
CEOJohn D. Quisel
Financial Highlights & Ratios
Gross Profit$-281K
EBITDA$-207.94M
Net Income$-212.18M
Operating Income$-236.02M
Total Cash$791.15M
Total Debt$1.86M
Net Debt$-89.28M
Total Assets$806.88M
Price / Earnings (P/E)-11.7
Analyst Forecast
1Y Price Target$112.00
Target High$153.00
Target Low$75.00
Upside+58.9%
Rating ConsensusBuy
Analysts Covering11
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS2546041011

Price Chart

Track all markets on TradingView
IRON
Disc Medicine, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
30.82 52WK RANGE 99.50

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 GPCR
GPCR
Structure Therapeutics Inc.
$53.19
-1.95%
 MORF
MORF
Morphic Holding, Inc.
$56.99
+0.04%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message